Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 28, 2014; 20(16): 4681-4691
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4681
Published online Apr 28, 2014. doi: 10.3748/wjg.v20.i16.4681
Table 6 Treatment side effects n (%)
| Side effect | n = 46 |
| Flu like symptoms | 15 (32.6) |
| Headache | 15 (32.6) |
| Fever | 27 (58.7) |
| Injection site reaction | 7 (15.2) |
| Itching | 1 (2.2) |
| Fainting | 1 (2.2) |
| Vomiting | 6 (13) |
| Nervousness | 1 (2.2) |
| Loss of appetite | 10 (21.7) |
| Sleeplessness | 1 (2.2) |
| Rigors | 3 (6.5) |
| Neutropenia | 6 (13) |
| Anemia (Hb 8.5-10 g/dL) | 8 (17.4) |
| Anemia (Hb ≤ 8.5 g/dL) | 2 (4.3) |
| Abdominal pain | 2 (4.3) |
| Arthralgia | 5 (10.9) |
| Diarrhea | 4 (8.7) |
-
Citation: Naghi SE, Abdel-Ghaffar TY, El-Karaksy H, Abdel-Aty EF, El-Raziky MS, Allam AA, Helmy H, El-Araby HA, Behairy BE, El-Guindi MA, El-Sebaie H, Abdel-Ghaffar AY, Ehsan NA, El-Hennawy AM, Sira MM. Safety and efficacy of
Hansenula -derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. World J Gastroenterol 2014; 20(16): 4681-4691 - URL: https://www.wjgnet.com/1007-9327/full/v20/i16/4681.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i16.4681